YM BioSciences Inc., an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, announced that the clinical hold imposed by the US Food and Drug Administration (FDA) on the development of YM's AeroLEF has been lifted.

The lifting of this hold permits YM to resume the expansion into the US of the phase II clinical development of AeroLEF.

AeroLEF is being developed as a novel and effective approach to the management of acute pain by delivering a proprietary formulation of inhaled, nebulized, free-and-liposome-encapsulated fentanyl. The free fentanyl results in rapid onset of analgesia while the liposome-encapsulated fentanyl produces the unique extended duration of pain relief. The FDA cleared a phase II protocol in June 2007 to proceed with AeroLEF's first trial in the US, however, immediately prior to the End-of-phase II meeting scheduled and held in January 2008, the FDA imposed a Clinical Hold, now lifted.

YM is also pleased to announce that Dr Ali Raza has been engaged as president of the AeroLEF Division to lead the product's further development. Dr Raza has held a number of leadership roles in established and development-stage pharmaceutical companies. He led the global development of Crestor (rosuvastatin), a product approved in more than 60 countries and which is competing for market leadership with Lipitor. Earlier this year he achieved regulatory clearance for and initiated a major phase III clinical programme for a fentanyl product being developed in more than 50 research centres in Europe.

"I am delighted to have joined the AeroLEF team at YM BioSciences and look forward to moving rapidly to the late-stage, international development of this unique product," said Dr Raza.

"We welcome Dr Raza and have high confidence that his breadth of experience in global drug development will significantly reinforce our team's ability to realize the substantial value of AeroLEF's unique approach to the treatment of pain. The scientific pedigree and unique advantages of this product have been established and safety and efficacy data have been reported from previous clinical trials, including in three poster presentations at the Annual Meeting of the American Pain Society in May 2008," said David Allan, chairman and CEO. "We also greatly appreciate the timely review by the FDA to our responses and the constructive approach of the Agency".